You are here

DRUG DISCOVERY PLATFORM FOR PROTEIN ARGININE METHYLTRANSFERASE INHIBITORS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41GM121174-01
Agency Tracking Number: R41GM121174
Amount: $157,500.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA15-270
Timeline
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-01
Award End Date (Contract End Date): 2018-08-31
Small Business Information
1416 SWEET HOME RD STE 3
Buffalo, NY 14228-2784
United States
DUNS: 805696189
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 JOHN ALETTA
 (716) 881-8948
 jmaletta@ch3biosystems.com
Business Contact
 JOHN ALETTA
Phone: (716) 881-8948
Email: jmaletta@ch3biosystems.com
Research Institution
N/A
Abstract

Project Summary Abstract
The long term objective of this project is the generation of a universal drug discovery platform
based on protein arginine methylation mechanisms involved in human disease The importance of
protein arginine methylation in the context of human disease has become clear in the last few years with
the realization that protein arginine methyltransferases and the target proteins for these enzymes are a
rich source of potential therapeutic targets
The specific aims of the project are to produce a general high throughput screening method
for identifying potent inhibitors of protein arginine methyltransferases and to generate the means for
isolating and identifying cellular methylarginine proteins for the purpose of determining the methylation
status of specific proteins The methods include a combination of high throughput screening of enzyme
inhibitors and biochemical immunological biophysical and cell biology techniques to isolate identify
quantify and characterize methylarginine protein biomarkers The final phase of the project will analyze
the methylarginine proteins of human blood cells drawn from normal volunteers and patients diagnosed
with the autoimmune disease scleroderma
This research is relevant to millions of Americans afflicted with autoimmune disorders as well
as neurodevelopmental syndromes and viral neoplastic and cardiovascular disease Elucidation of the
role of protein arginine methylation in these diseases holds promise for better diagnosis understanding
and treatment of health related problems Project Narrative
The purpose of this project is the development of a commercial technology that will facilitate the
discovery screening and further testing of new first in class drugs There are at least five areas of
medicine that are likely to be impacted by the technology autoimmune disorders neurodevelopmental
syndromes and viral neoplastic and cardiovascular diseases The long term goal of the project is better
diagnosis understanding and treatment of health related problems by promoting more rapid advances in
Randamp D and molecular diagnostics

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government